SCHEDULE: Intracoastal Capital Discloses 9.99% Stake in Bluejay Diagnostics

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a 9.99% passive ownership stake in Bluejay Diagnostics, Inc. common stock.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have disclosed beneficial ownership of Bluejay Diagnostics, Inc. Common Stock.
• The Reporting Persons collectively beneficially own 177,580 shares of Common Stock, representing 9.99% of the class.
• This ownership includes 175,000 shares of Common Stock held by Intracoastal Capital LLC and 2,580 shares issuable upon exercise of Intracoastal Warrant 1.
• The percentage of ownership is calculated based on 1,600,000 shares outstanding prior to a Securities Purchase Agreement (SPA) transaction, plus 175,000 shares issued to Intracoastal, and 2,580 shares from the exercisable warrant.
• The Reporting Persons also hold additional warrants (Intracoastal Warrant 1, 2, 3, and 4) that would collectively represent 1,125,069 shares if fully exercised without blocker provisions.
• However, these warrants contain blocker provisions limiting beneficial ownership to 9.99% or 4.99% to prevent exceeding certain thresholds upon exercise.
• The filing is a Schedule 13G, indicating that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by a group of investors, including Intracoastal Capital LLC, in Bluejay Diagnostics, Inc. This suggests a vote of confidence and likely provided capital to the company through the Securities Purchase Agreement. The presence of blocker provisions in warrants indicates a strategic approach to maintaining a passive stake while retaining potential for future ownership.

Positives

• A group of investors, including Intracoastal Capital LLC, has acquired a significant 9.99% passive stake in Bluejay Diagnostics, Inc., potentially signaling confidence in the company's prospects.
• The beneficial ownership stems from a Securities Purchase Agreement (SPA) transaction on October 10, 2025, which likely provided capital to Bluejay Diagnostics, Inc. for its operations and strategic initiatives.

Negatives

• The reporting persons are limited to a 9.99% beneficial ownership due to blocker provisions in their warrants, preventing immediate exercise of a larger potential stake.

Risks

• NA

Future Outlook

NA

Industry Context

NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The entry of a new significant investor could be seen positively, potentially increasing liquidity or signaling future growth. The capital raise (implied by SPA) could dilute existing shareholders but also fund operations.
• Company (Bluejay Diagnostics): Received capital from the SPA, which can support operations and strategic initiatives.

Next Steps

• NA

Key Dates

Recommendation

The filing indicates a significant passive investment by Intracoastal Capital LLC and its affiliates in Bluejay Diagnostics, Inc., acquiring a 9.99% stake. While this suggests a vote of confidence and likely provided capital to the company, the passive nature of the investment and the presence of blocker provisions in warrants limit immediate influence or aggressive accumulation. Without further details on the terms of the Securities Purchase Agreement, the company's financial health, or strategic plans, a "hold" recommendation is appropriate, acknowledging the positive signal of new investment while awaiting more comprehensive information for a stronger stance.

Keywords

Bluejay Diagnostics, Intracoastal Capital, Mitchell Kopin, Daniel Asher, Schedule 13G, beneficial ownership, common stock, equity stake, passive investment, SEC filing, warrants